Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
Download image INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14.
Lilly is working with the U.S. Food and Drug Administration's Office of Criminal Investigations (FDA), and other law enforcement officials, to recover cases of select lots of pharmaceutical products that were stolen from one of Lilly's United States distribution centers located in Enfield, Connecticut, on Sunday, March 14, 2010. A list of products stolen from the facility can be found at the bottom of this press release.
"Since early Sunday morning, Lilly has taken quick and appropriate actions to ensure the safety of our medicines," said Dr. Fionnuala M. Walsh, Lilly's senior vice president of global quality. "The U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels. However, we will continue to work closely with local and federal law enforcement authorities, the FDA, and our distribution partners to maintain the integrity of our drug supply chain."
Product from the affected lots which had been delivered from Lilly to retailers, wholesalers or institutions prior to March 14 was approved for its intended use and is not affected by this event. Product containing these lot numbers has been distributed by Lilly within the United States, Puerto Rico and its territories.
These medicines require a prescription for purchase. Consumers should purchase Lilly products only from well-established and reputable retailers. Lilly recommends that consumers always inspect the product and label for signs of tampering before opening.
Lilly is advising practitioners, retailers and consumers to check all pharmaceutical products for signs of tampering or damage prior to purchase and/or use. Pharmacists and other health care professionals should not use the product if it has been removed from the sealed bottle or container, if the induction seal has been compromised, or in the case of glass vials, if the flip cap appears to have been disturbed in any way.
To assist the FDA and the law enforcement agencies in their investigation, Lilly stopped distributing product with the affected lot numbers on Monday, March 15, 2010.
Lilly is asking for the public's help in reporting any information regarding the stolen products to FDA's Office of Criminal Investigations (OCI) by calling (800) 551-3989 or by visiting the OCI website www.fda.gov/OCI.
For medical or other related inquiries about this matter, contact Lilly at 1-800-LILLYRX (1-800-545-5979).
Impacted Products
National Drug Code
Product Description (NDC) Lot Number Expiry Date
------------------- ------------------ ---------- -----------
ALIMTA FINJ 500MG X1
lyophilizedVIAL AM 00002-7623-01 A671076C 8/31/2011
-------------------- ------------- -------- ---------
CYMBALTA CAP 30MG X 30
BTL AM 00002-3240-30 A643056A 5/31/2012
---------------------- ------------- -------- ---------
CYMBALTA CAP 30MG X 30
BTL AM 00002-3240-30 A662278C 7/31/2012
---------------------- ------------- -------- ---------
CYMBALTA CAP 30MG X 30
BTL AM 00002-3240-30 A662281A 7/31/2012
---------------------- ------------- -------- ---------
CYMBALTA CAP 60MG X30BOTL
AM 00002-3270-30 A672999A 9/30/2011
------------------------- ------------- -------- ---------
CYMBALTA CAP 60MG
X1000BOTL AM 00002-3270-04 A685790A 10/31/2011
----------------- ------------- -------- ----------
EFFIENT TAB 10MG X30BOTL
AM 00002-4759-30 A650259A 12/31/2010
------------------------ ------------- -------- ----------
GEMZAR 200MG VIALS 00002-7501-01 A670185A 8/31/2011
------------------ ------------- -------- ---------
GEMZAR 1 GRAM VIALS 00002-7502-01 A668160D 8/31/2011
------------------- ------------- -------- ---------
GEMZAR 1 GRAM VIALS 00002-7502-01 A670177A 9/30/2011
------------------- ------------- -------- ---------
GEMZAR 1 GRAM VIALS 00002-7502-01 A670180A 8/31/2011
------------------- ------------- -------- ---------
GEMZAR 1 GRAM VIALS 00002-7502-01 A670182A 9/30/2011
------------------- ------------- -------- ---------
PROZAC PULV 20MG X 30
BOTL DP 00777-3105-30 A599046D 1/31/2012
--------------------- ------------- -------- ---------
PROZAC PULV 20MG X 30
BOTL DP 00777-3105-30 A689619D 10/31/2012
--------------------- ------------- -------- ----------
PROZAC PULV 40MG X 30
BOTL DP 00777-3107-30 A602567A 1/31/2012
--------------------- ------------- -------- ---------
STRATTERA CAP 10MG X 30
BOTL AM 00002-3227-30 A621189A 3/31/2012
----------------------- ------------- -------- ---------
STRATTERA CAP 25MG X 30
BOTL AM 00002-3228-30 A678353A 2/29/2012
----------------------- ------------- -------- ---------
STRATTERA CAP 60MG X 30
BOTL AM 00002-3239-30 A621202A 3/31/2012
----------------------- ------------- -------- ---------
STRATTERA CAP 100MG
X30BOTL AM 00002-3251-30 A621205C 3/31/2012
------------------- ------------- -------- ---------
SYMBYAX CAP 6/25MG X 30
BOTL AM 00002-3231-30 A562684A 10/31/2011
----------------------- ------------- -------- ----------
ZYPREXA TAB 2.5MG X30BOTL
AM 00002-4112-30 A644710A 5/31/2011
------------------------- ------------- -------- ---------
ZYPREXA TAB 5MG X30BOTL
AM 00002-4115-30 A668322A 8/31/2011
----------------------- ------------- -------- ---------
ZYPREXA TAB 7.5MG X30BOTL
AM 00002-4116-30 A646193A 5/31/2011
------------------------- ------------- -------- ---------
ZYPREXA TAB 10MG X30BOTL
AM 00002-4117-30 A641350C 5/31/2012
------------------------ ------------- -------- ---------
ZYPREXA TAB 10MG X30BOTL
AM 00002-4117-30 A668323A 8/31/2012
------------------------ ------------- -------- ---------
ZYPREXA TAB 15MG X 1000
BOTL AM 00002-4415-04 A647860A 5/31/2012
----------------------- ------------- -------- ---------
ZYPREXA TAB 15MG X30BOTL
AM 00002-4415-30 A690238A 10/31/2012
------------------------ ------------- -------- ----------
ZYPREXA TAB 20MG X30BOTL
AM 00002-4420-30 A677956A 8/31/2012
------------------------ ------------- -------- ---------
ZYPREXA TAB 20MG X30BOTL
AM 00002-4420-30 A677958C 8/31/2012
------------------------ ------------- -------- ---------
ZYPREXA TAB ID100 10MG
XID100BLCD AM 00002-4117-33 A632252D 4/30/2012
---------------------- ------------- -------- ---------
ZYPREXA ZYDIS TAB 5MG X
30 SACH AM 00002-4453-85 976041A 7/1/2012
----------------------- ------------- ------- --------
ZYPREXA ZYDIS TAB 10MG X
30 SACH AM 00002-4454-85 971159A 7/1/2012
------------------------ ------------- ------- --------
ZYPREXA ZYDIS TAB 20MG X
30 SACH AM 00002-4456-85 963999A 5/1/2012
------------------------ ------------- ------- --------
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY
Alimta® (pemetrexed disodium)
Cymbalta® (duloxetine hydrochloride)
EffientTM (prasugrel)
Gemzar® (gemcitabine hydrochloride)
Prozac® (fluoxetine hydrochloride)
Strattera® (atomoxetine hydrochloride)
Symbyax (olanzapine / fluoxetine hydrochloride)
Zyprexa® (olanzapine)